Search Result

Results for "

DM1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (3) ADC Linker (2) Aldose Reductase (1) Amylases (1) Antibody-Drug Conjugates (ADCs) (5) Apoptosis (1) Dipeptidyl Peptidase (4) Drug-Linker Conjugates for ADC (13) EGFR (2) Estrogen Receptor/ERR (2) Free Fatty Acid Receptor (1) GCGR (5) Glucosidase (3) GPR119 (1) Ketohexokinase (1) Microtubule/Tubulin (4) PARP (1) Phosphatase (1) SGLT (2) Somatostatin Receptor (3) Target Protein Ligand-Linker Conjugates (2) Wnt (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (1) Endocrinology (4) Inflammation/Immunology (1) Metabolic Disease (25)
Click Chemistry:	DBCO (2)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19792

Mertansine Maximum Cited Publications 20 Publications Verification DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) ^[1] .

HY-101070

SMCC-DM1 5+ Cited Publications DM1-SMCC	Drug-Linker Conjugates for ADC	Cancer
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) ^[1].

HY-100128

DM1-SMe	Microtubule/Tubulin ADC Cytotoxin	Cancer
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC₅₀s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines ^[1].

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-100504

S-methyl DM1	Microtubule/Tubulin ADC Cytotoxin	Cancer
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a K_d of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects ^[1] .

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer ^[1] .

HY-101982A

(Rac)-Lys-SMCC-DM1 (Rac)-Lys-Nε-MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1 ^[1].

HY-132250

MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues ^[1] .

HY-136286

MC-DM1	Drug-Linker Conjugates for ADC	Cancer
MC-DM1 is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody agent conjugate (ADC) ^[1].

HY-W190944

DM1-MCC-PEG3-Biotin	Drug-Linker Conjugates for ADC	Cancer
DM1-MCC-PEG3-Biotin is a drug-linker conjugate for ADC.

HY-126491

SPP-DM1	Drug-Linker Conjugates for ADC	Cancer
SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP ^[1].

HY-147094

vc-PABC-DM1	ADC Linker	Cancer
vc-PABC-DM1 used to synthesize an ADC molecule based on utilize disulfide linker. vc-PABC-DM1 can be used to explore serum stability ^[1].

HY-126693

SC-VC-PAB-DM1	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB ^[1].

HY-126682

Mal-VC-PAB-DM1 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB ^[1].

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[1] .

HY-136260

DBCO-PEG4-Ahx-DM1	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-147050

Ahx-DM1	Target Protein Ligand-Linker Conjugates	Others
Ahx-DM1 (compound 2A) is a conjugate of protein/peptide which can be combined with a therapeutic, diagnostic or labelling agent ^[1].

HY-132260

Naratuximab emtansine IMGN529; Debio 1562	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis ^[1].

HY-147050A

*Ahx-DM1* TFA**	Target Protein Ligand-Linker Conjugates	Others
Ahx-DM1 (TFA) (compound 2A) is a conjugate of protein/peptide which can be combined with a therapeutic, diagnostic or labelling agent ^[1].

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts ^[1] .

HY-128951

AMCC-DM1	Drug-Linker Conjugates for ADC	Cancer
AMCC-DM1 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker AMCC to make antibody drug conjugate. AMCC is a noncleavable linker ^[1].

HY-132262

Lorvotuzumab mertansine IMGN-901; BB-1090	Antibody-Drug Conjugates (ADCs)	Cancer
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity ^[1].

HY-P9921

Trastuzumab emtansine 2 Publications Verification Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[1] .

HY-132251

MCC	ADC Linker	Cancer
MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1 ^[1].

HY-128960

DBA-DM4	Drug-Linker Conjugates for ADC	Cancer
DBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM1 and a linker SPDP to make antibody agent conjugate (ADC) ^[1].

HY-107502

Cryptophycin analog 1	Others	Cancer
Cryptophycin analog 1 is an ADC payload. Cryptophycin analog 1 shows anticancer activity. Cryptophycin analog 1 displays cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1 ^[1].

HY-14928

Lobeglitazone	Others	Metabolic Disease
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-14928A

Lobeglitazone sulfate	Others	Metabolic Disease
Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-19947

PF-06291874 1 Publications Verification Glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-153865

Lotiglipron PF-07081532	GCGR	Metabolic Disease
Lotiglipron (PF-07081532) is an orally active *GLP-1R* agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .

HY-163886

KHK-IN-5	Ketohexokinase	Metabolic Disease
KHK-IN-5 (Compound 18) is a KHK inhibitor. KHK-IN-5 can be used for the research of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2DM) .

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-114191

SSTR5 antagonist 2	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-114191A

SSTR5 antagonist 2 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-155344

α-Glucosidase-IN-38	Glucosidase	Metabolic Disease
α-Glucosidase-IN-38 (Compound 11j) is a potent inhibitor of α-glucosidase inhibitor with IC₅₀ of 12.44±0.38 μM.α-Glucosidase-IN-38 plays an important role in Diabetes mellitus (DM) .

HY-15408

Trelagliptin SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-15408A

Trelagliptin succinate SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-12066

GSK1292263 3 Publications Verification	GPR119	Metabolic Disease Inflammation/Immunology
GSK-1292263 is an orally available GPR119 agonist with pEC₅₀s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-147257

Cofrogliptin HSK7653	Dipeptidyl Peptidase	Metabolic Disease
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .

HY-149332

α-Glucosidase-IN-26	Glucosidase	Metabolic Disease
α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC₅₀=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM) .

HY-128781

Glucagon receptor antagonists-5	GCGR	Metabolic Disease
Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (K_i=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-159696A

ISIS 449884 sodium	GCGR	Metabolic Disease
ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159696

ISIS 449884	GCGR	Metabolic Disease
ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-162673

α-Amylase/α-Glucosidase-IN-16	Amylases Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of α-amylase and α-Glucosidase with IC₅₀ values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .

HY-15408AR

Trelagliptin succinate (Standard)	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (succinate) (Standard) is the analytical standard of Trelagliptin (succinate). This product is intended for research and analytical applications. Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-19835

LY2922470	Free Fatty Acid Receptor	Metabolic Disease
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC₅₀s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .

HY-132205

DS45500853	Estrogen Receptor/ERR	Metabolic Disease
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC₅₀ value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) .

Cat. No.	Product Name	Type

HY-W587977

3-Hydroxypalmitoylcarnitine 3-Hydroxyhexadecanoylcarnitine	Biochemical Assay Reagents
3-Hydroxypalmitoylcarnitine (3-Hydroxyhexadecanoylcarnitine) is an acylcarnitine. Elevated levels of 3-Hydroxypalmitoylcarnitine are associated with cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) .

Cat. No.	Product Name	Target	Research Area

HY-P10567

Pip6a	Peptides	Others
Pip6a is an arginine-rich cell-penetrating peptide. Pip6a has the ability to deliver associated cargoes across the plasma and endosomal membranes and is stable to serum proteolysis. Pip6a is composed of a hydrophobic core region flanked on each side by arginine-rich domains containing β-alanine and aminohexanoyl spacers. Pip6a-conjugated morpholino phosphorodiamidate oligomer (PMO) dramatically enhanced antisense oligonucleotide (ASO) delivery into striated muscles of myotonic dystrophy (DM1) mice ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts ^[1] .

HY-132260

Naratuximab emtansine IMGN529; Debio 1562	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Classification of Application Fields Disease Research Fields Cancer	Antibody-Drug Conjugates (ADCs) EGFR
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer ^[1] .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81055

	DM1 Antibody (YA898) Mertansine, Maytansinoid DM1, DM 1, 139504-50-0	ELISA	Species independent
	DM1 Antibody (YA898) is an unconjugated, mouse-derived, anti-DM1 (YA898) monoclonal antibody. DM1 Antibody (YA898) can be used for: ELISA expriments without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-136261

DM1-PEG4-DBCO		DBCO
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136260

DBCO-PEG4-Ahx-DM1		DBCO
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-159696A

ISIS 449884 sodium		Antisense Oligonucleotides
ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159696

ISIS 449884		Antisense Oligonucleotides
ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

DM1

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products